RxDoctor Payments Data

Kevin Harbour, MD

Pulmonary Disease · Tupelo, MSNPI 1508903626

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $8,244 of the $12,828 with a category attached, or 64.3%. 43 manufacturers reported payments, led by Intuitive Surgical at 36.7% of the total. Reporting peaked in 2023 at $5,967 and has fallen 70.0% since, to $1,788 in 2025.

$12,828in general payments, 2019–2025

Across 468 payments — averaging $27.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$5K
  • GSK$1K
  • AstraZeneca$1K
  • Boehringer Ingelheim$958
  • Actelion Pharmaceuticals US, Inc.$337
  • Merck$321
  • plus $4K from 37 others

What the payments were for

  • Speaking & faculty fees$3002%
  • Travel & lodging$1,0298%
  • Food & beverage$8,24464%
  • Education$3,25525%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,828 in reported general payments places this provider in the 75th percentile of 101 pulmonary disease providers in Mississippi.

See all pulmonary disease providers in Mississippi

Medicare billing

Part B allowed, 2024
$163,924
Medicare patients
710
Services billed
2,333

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter340$252,235
GlassiaAlpha-1-Proteinase Inhibitor13$191,509
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr86$41,575
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$16,410
Breo ElliptaFluticasone/Vilanterol26$12,094
Stiolto RespimatTiotropium Br/Olodaterol Hcl15$7,522
Albuterol Sulfate HfaAlbuterol Sulfate177$5,704
SymbicortBudesonide/Formoterol Fumarate11$3,461
Ventolin HfaAlbuterol Sulfate45$2,362
Wixela InhubFluticasone Propion/Salmeterol12$1,409
Fluticasone-SalmeterolFluticasone Propion/Salmeterol12$739
Montelukast Sodium59$292
Azithromycin48$200
Prednisone67$137
Fluticasone Propionate16$100

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$1,494$305,905452 claims
Takeda Pharmaceuticals U.S.A., Inc.Glassia$152$191,50913 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,148$19,87138 claims
Boehringer IngelheimStiolto Respimat$958$7,52215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 101 pulmonary disease providers in Mississippi.

Other pulmonary disease in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →